PD-1 Blockers.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 26317459.
- Also identified by DOI 10.1016/j.cell.2015.07.045.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Nivolumab and pembrolizumab are monoclonal antibodies that block the programmed death-1 receptor (PD-1, CD279), resulting in dis-inhibition of tumor-specific immune responses. Both are recently approved for use in the treatment of metastatic melanoma, and nivolumab as well for non-small cell lung cancer.
Medical subject headings
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Melanoma
- Programmed Cell Death 1 Receptor
- Skin Neoplasms